RetaCalc
Protocol library
BlendNot ApprovedMixedVery Low confidenceSourced

BPC-157 / TB-500 blend

A combined research product without controlled human evidence for the mixture. Component-level preclinical claims do not establish compatibility or a blend protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for an equal 5 mg plus 5 mg blend

600 mcg total daily in weeks 1-2, 800 mcg in weeks 3-4 and 600 mcg in weeks 5-8, delivering equal mass of each component

This is a community blend convention with no controlled human mixture study. It cannot establish component identity, compatibility or a validated outcome.

View source

Evidence summary

A combined research product without controlled human evidence for the mixture. Component-level preclinical claims do not establish compatibility or a blend protocol.

Protocol basis

The evidence is assessed component by component because no matched human trial of the blend was found. Neither component supplies a validated routine protocol.

What remains uncertain

Combined pharmacokinetics, chemical compatibility, stability, safety and clinical outcomes are unknown.

Warnings and contraindications

No adequate controlled human study of the combined formulation was identified.
BPC-157 and TB-500 each have major evidence and product-identity gaps.
Mixing adds unresolved stability, sterility, compatibility and exposure questions.